Cargando…
Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
OBJECTIVES: China has a high burden of drug-resistant tuberculosis (TB). As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663430/ https://www.ncbi.nlm.nih.gov/pubmed/29088241 http://dx.doi.org/10.1371/journal.pone.0187076 |
_version_ | 1783274810420232192 |
---|---|
author | Xu, Lin Chen, Jinou Innes, Anh L. Li, Ling Chiang, Chen-Yuan |
author_facet | Xu, Lin Chen, Jinou Innes, Anh L. Li, Ling Chiang, Chen-Yuan |
author_sort | Xu, Lin |
collection | PubMed |
description | OBJECTIVES: China has a high burden of drug-resistant tuberculosis (TB). As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan. METHODS: We applied multistage cluster sampling using probability proportion to size to select 28 counties in Yunnan. Consecutive pulmonary TB patients were enrolled from either the TB centers of Yunnan Center of Disease Control or designated TB hospitals. Outcomes of interest included the regimen used in the treatment of new and retreatment TB patients; and the proportion of patients treated with adequate dosing of anti-TB drugs. Furthermore, we assess whether there has been reduction in the use of fluoroquinolone and second line injectables in Tuberculosis Clinical Centre (TCC) after the training activity in late 2012. RESULTS: Of 2390 TB patients enrolled, 582 (24.4%) were prescribed second line anti-TB drugs (18.0% in new cases and 60.9% in retreatment cases); 363(15.2%) prescribed a fluoroquinolone. General hospitals (adjusted odds ratio (adjOR) 1.97, 95% confidence interval (CI) 1.47–2.66), retreatment TB cases (adjOR 4.75, 95% CI 3.59–6.27), smear positive cases (adjOR 1.69, 95% CI 1.22–2.33), and extrapulmonary TB (adjOR 2.59, 95% CI 1.66–4.03) were significantly associated with the use of fluoroquinolones. The proportion of patients treated with fluoroquinolones decreased from 41.4% before 2013 to 13.5% after 2013 (adjOR 0.19, 95% CI 0.12–0.28) in TCC. The proportion of patients with correct, under and over dosages of isoniazid was 88.2%, 1.5%, and 10.4%, respectively; of rifampicin was 50.2%, 46.8%, and 2.9%; of pyrazinamide was 67.6%, 31.7% and 0.7%; and of ethambutol was 41.4%, 57.5%, and 1.0%. CONCLUSIONS: The prescribing practice of anti-TB drugs was not standardized, findings with significant programmatic implication. |
format | Online Article Text |
id | pubmed-5663430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56634302017-11-09 Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit Xu, Lin Chen, Jinou Innes, Anh L. Li, Ling Chiang, Chen-Yuan PLoS One Research Article OBJECTIVES: China has a high burden of drug-resistant tuberculosis (TB). As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan. METHODS: We applied multistage cluster sampling using probability proportion to size to select 28 counties in Yunnan. Consecutive pulmonary TB patients were enrolled from either the TB centers of Yunnan Center of Disease Control or designated TB hospitals. Outcomes of interest included the regimen used in the treatment of new and retreatment TB patients; and the proportion of patients treated with adequate dosing of anti-TB drugs. Furthermore, we assess whether there has been reduction in the use of fluoroquinolone and second line injectables in Tuberculosis Clinical Centre (TCC) after the training activity in late 2012. RESULTS: Of 2390 TB patients enrolled, 582 (24.4%) were prescribed second line anti-TB drugs (18.0% in new cases and 60.9% in retreatment cases); 363(15.2%) prescribed a fluoroquinolone. General hospitals (adjusted odds ratio (adjOR) 1.97, 95% confidence interval (CI) 1.47–2.66), retreatment TB cases (adjOR 4.75, 95% CI 3.59–6.27), smear positive cases (adjOR 1.69, 95% CI 1.22–2.33), and extrapulmonary TB (adjOR 2.59, 95% CI 1.66–4.03) were significantly associated with the use of fluoroquinolones. The proportion of patients treated with fluoroquinolones decreased from 41.4% before 2013 to 13.5% after 2013 (adjOR 0.19, 95% CI 0.12–0.28) in TCC. The proportion of patients with correct, under and over dosages of isoniazid was 88.2%, 1.5%, and 10.4%, respectively; of rifampicin was 50.2%, 46.8%, and 2.9%; of pyrazinamide was 67.6%, 31.7% and 0.7%; and of ethambutol was 41.4%, 57.5%, and 1.0%. CONCLUSIONS: The prescribing practice of anti-TB drugs was not standardized, findings with significant programmatic implication. Public Library of Science 2017-10-31 /pmc/articles/PMC5663430/ /pubmed/29088241 http://dx.doi.org/10.1371/journal.pone.0187076 Text en © 2017 Xu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Xu, Lin Chen, Jinou Innes, Anh L. Li, Ling Chiang, Chen-Yuan Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit |
title | Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit |
title_full | Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit |
title_fullStr | Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit |
title_full_unstemmed | Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit |
title_short | Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit |
title_sort | prescription practice of anti-tuberculosis drugs in yunnan, china: a clinical audit |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663430/ https://www.ncbi.nlm.nih.gov/pubmed/29088241 http://dx.doi.org/10.1371/journal.pone.0187076 |
work_keys_str_mv | AT xulin prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit AT chenjinou prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit AT innesanhl prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit AT liling prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit AT chiangchenyuan prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit |